Tags: Pembrolizumab
Immunotherapy in Esophagogastric Cancer
Abstract: The uses of immune checkpoint inhibitors have now been advanced to include the first-line treatment of esophagogastric cancers. Initially approved for the treatment of chemotherapy-refractory […]
Hem/Onc News
Entrectinib Approved for NTRK Fusion–Positive Solid Tumors and ROS1-Rearranged Non–Small Cell Lung Cancer On August 15, the US Food and Drug Administration (FDA) granted approval to […]
Hem/Onc News
Selinexor Approved for Multiple Myeloma On July 3, the US Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio, Karyopharm) in combination with dexamethasone […]
Hem/Onc News
Pembrolizumab Receives Regular Approval in Metastatic Nonsquamous NSCLC On August 20, the US Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda, Merck) for […]
Weight-Based Dosing vs Fixed Dosing of Pembrolizumab: an Economic Analysis
H&O When were the first checkpoint inhibitors approved by the FDA? DG Immunotherapy has been an important breakthrough of the past few years. The cytotoxic […]
Hem/Onc News
First Biosimilar to Pegfilgrastim Approved to Decrease Risk for Infection During Cancer Treatment On June 4, the US Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila, […]
Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium
Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 8-10, 2018 • San Francisco, California Atezolizumab Plus Bevacizumab Improves Progression-Free Survival […]
Hem/Onc News
Recombinant Factor IX Approved for Use in Adults and Children With Hemophilia B The US Food and Drug Administration (FDA) approved the recombinant coagulation factor IX […]